05 December 2017

AWC Singapore 2018 – Accepted abstract submissions

abstracts 4.jpg

We are delighted to announce the following abstracts have been accepted: 

  • Investigation of survival status and analysis of social influence factors on discharged patients with pulmonary arterial hypertension
  • The specialty of pulmonary vascular medicine in China: Historical development and future directions
  • Outcomes of atrial flow regulator implantation in patients with severe pulmonary hypertension
  • Atrial septal defect associated pulmonary arterial hypertension: outcomes of closure with a fenestrated device
  • New evidence of genetic adaptation to high altitude in Andean populations
  • First identification of Krüppel-like factor 2 mutation in heritable pulmonary arterial hypertension
  • Identification of genetic defects in pulmonary arterial hypertension by a new panel diagnostic
  • Hypoxia-induced pulmonary hypertension in C57BL/6J and C57BL/6N mice: is there any difference?
  • Stem cell based drug screening for pulmonary arterial hypertension
  • 3’UTR shortening in the Pathogenesis of Pulmonary Hypertension
  • Early detection of pulmonary arterial hypertension in patients with systemic connective tissue disease
  • Reactive pulmonary hypertension induced by the left heart failure in the rats
  • Transition to oral from intravenous prostacyclins therapy in pulmonary arterial hypertension
  • Spironolactone use in a large cohort of PAH patients: results from clinical trial database
  • Upregulation of CHK1 in PAH-PASMCs is essential for proliferation and survival by promoting DNA repair mechanisms
  • Endothelium-protective effects of exosomal KLF2-induced micro RNAs: implications for treatment of pulmonary hypertension
  • Supplementation of miR-150 as potential therapeutic strategy in pulmonary arterial hypertension
  • Targeting CLIC/Arf6 signalling as a new therapeutic strategy in pulmonary hypertension.
  • A role for the bone morphogenetic protein type 2 receptor (BMPR2) in differentiation of the common myeloid progenitor lineage in mice and humans
  • Can idiopathic lymphoid interstitial pneumonia be a cause of moderate pulmonary hypertension?
  • Treatment of pulmonary hypertension in rats with Angiotensin II Receptor Blocker Neprilysin Inhibitor
  • The outcome of pregnancy in adult patients with pulmonary hypertension associated with uncorrected congenital heart disease – a substudy of Jogjakarta COHARD-PH registry, Indonesia
  • Reliability of Systolic Pulmonary Artery Pressure by Doppler Echocardiography Compared to Right Heart Catheterization in Patients with Atrial Aeptal Defect: Analysis in a Large Patient Population
  • Changes of plasma Angiotensin-(1-7) in patients with pulmonary arterial hypertension due to congenital heart disease before and after intervention closure
  • Pulmonary hypertension in normal breast feeding infants – the undefined public health problem of epidemic proportions
  • NMDA-type glutamate receptor activation promotes vascular remodeling and pulmonary arterial hypertension
  • Clinical characteristics, survival analysis and mortality predictors of patients with chronic thromboembolic pulmonary hypertension: a single center experience
  • An unusual case of pulmonary hypertension after bone marrow transplantation
  • Hypoxia Inducible Factor (HIF) Promotes Metabolic Remodeling and Proliferation in Lymphatic
    Endothelial Cells Isolated from an Ovine Model of Congenital Heart Disease (CHD) with Increased
    Pulmonary Blood Flow
  • Pulmonary hypertension outcomes in systemic  sclerosis;  update of the PHAROS  Registry
  • Is pulmonary hypertension (ph) in children at altitude different in relation with ph in children at low altitude or sea level?
  • Long follow up of children with pulmonary hypertension (ph) at altitude. the importance to live at low altitude
  • Prognostic importance of BNP levels in patients with pulmonary hypertension
  • Comparison of intravenous sildenafil with inhaled nitric oxide in acute vasodilator testing in patients with pulmonary arterial hypertension
  • Results of pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: the experience of “Attikon” University Hospital, Athens, Greece
  • The clinical profiles of our pulmonary arterial hypertension patients with survival over 10 years
  • Sharp-edge of pulmonary arterıal hypertensıon-eısenmenger syndrome:multısystem dısease
  • Turkish experience on balloon pulmonary angioplasty; BPA-related pulmonary injury, therapeutic strategy and potential reasons
  • POTTS shunt as a palliation for patients with idiopathic PAH
  • Assessment of right ventricular diastolic by tricuspid annular plane systolic excursion (TAPSE) and its prognostic value in patients with pulmonary arterial hypertension
  • Abernathy malformation: A potentially treatable cause of pulmonary hypertension
  • Oxidation of protein kinase G Iα in the lung mediates an endogenous adaptation to pulmonary hypertension
  • Pulmonary hypertension associated with congenital heart disease: translating natural history into pathobiology
  • Selective HDAC IIA inhibition augments MEF2 activity and improves survival in experimental pulmonary hypertension
  • High resolution MicroCT assessment of right ventricular function in experimental models of pulmonary hypertension
  • Changes in hemodynamics in two PAH-induced animal models.
  • Single center experience in the treatment of chronic thromboembolic pulmonary hypertension
  • A case with ortodexia – Paltypnea syndrome due to multiple pulmonary arterio-venous fistula
  • Efficacy and safety of the oral prostacyclin (IP) receptor agonist ralinepag in pulmonary arterial hypertension (PAH)
  • The use of aerosolized prostacyclins in critically-ill patients with right ventricular failure
  • RV diastolic stiffness as a novel marker of RV failure in idiopathic pulmonary arterial hypertension
  • Quantification of Pulmonary Vascular Response to Nitric Oxide using Computed Tomography
  • Abstract PH-COPD Dyspnea 2018
  • Role for long non-coding RNA H19 in the development of right ventricular failure associated with pulmonary arterial hyperten
  • Intensive care mortality prognostic model for pediatric pulmonary hypertension
  • Effects of HIV infection on pulmonary artery pressure in children
  • Replacement of ESP by mPAP to calculate right-ventricular –arterial coupling leads to underestimation of ESP and overestimation of Ees/Ea
  • Significant association of pressure-volume-loops derived right ventriculo-arterial coupling with right and leftventricular MRI-strain
  • PEGASUS - the effects of commercial air travel on patients suffering from pulmonary hypertension - a prospective, multicentric analysis
  • Diagnostic accuracy of echocardiography in pulmonary hypertension due to interstitial lung disease
  • Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model
  • Treatment with low-dose tacrolimus attenuates bleeding complications but not pulmonary hypertension in a patient with hereditary hemorrhagic telangiectasia
  • Supportive therapy within the modern treatment era of idiopathic pulmonary hypertension: Impact of long term oxygen supply
  • Cell-cycle inhibition for the therapy for pulmonary arterial hypertension
  • Lupus in a low-resource setting: pulmonary vasculitis may better predict prognosis
  • Genotype and phenotype of childhood idiopathic and heritable pulmonary arterial hypertension in China



Posters should be brought to the Congress and must adhere to the following format:

  • Portrait size
  • A0 (841mm x 1189mm).

Abstract awards

The two Best Clinical Abstracts and the two Best Basic Abstracts will be announced at the Gala Dinner, as well as the winner of the Butrous Foundation Young Investigator Award for the overall best abstract. Recipients of the Travel Grant Award will be notified individually shortly. 


Comments (1)

  • profile picture of Deborah Quinn

    26 January 2018 19:03

    Deborah Quinn

    Can we get copy of the abstracts? I am especially interested in the Supportive Therapy and Oxygen use. I forgot to go talk to the presenter. I was busy with my poster! Debbie Quinn

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI